<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by 11.2 Capital on Medium]]></title>
        <description><![CDATA[Stories by 11.2 Capital on Medium]]></description>
        <link>https://medium.com/@112capital?source=rss-d78fc58d1c2b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*oQ7ok-wT_xNMqlZVE6ugeg.jpeg</url>
            <title>Stories by 11.2 Capital on Medium</title>
            <link>https://medium.com/@112capital?source=rss-d78fc58d1c2b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sun, 22 Nov 2026 19:05:41 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@112capital/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Data-Driven Health 2]]></title>
            <link>https://medium.com/@112capital/data-driven-health-2017-e668c82e37d5?source=rss-d78fc58d1c2b------2</link>
            <guid isPermaLink="false">https://medium.com/p/e668c82e37d5</guid>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[11.2 Capital]]></dc:creator>
            <pubDate>Sat, 30 Dec 2017 21:06:53 GMT</pubDate>
            <atom:updated>2019-02-05T04:57:43.992Z</atom:updated>
            <content:encoded><![CDATA[<p>Almost a year ago, we published our perspective on the data-driven health landscape. Since then we’ve continued to seek out opportunities that advance precision medicine by bringing together interdisciplinary fields across biology, engineering, data science, and clinical care. We looked into optimizing synthetic biology as a tool with industrial and therapeutic applications, as well as the consumerization of diagnostics for senior care. We explored ways to read from and write to our brain in the field of neurotech and brain-computer interfaces. Lastly, we continued to see ways machine learning is shortening time and reducing cost in drug development.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*f-tulhszP3Qouxbuo5-sIQ.jpeg" /><figcaption>Full resolution of the landscape can be found <a href="https://drive.google.com/file/d/1qvqXcZ3rQxCtHKzmsfCEHhqFUyLpvm5g/view?usp=sharing">here</a></figcaption></figure><p><strong>Synthetic Biology</strong></p><p>Biology experiments generate massive amount of data, especially in research and development setting. Wet lab experiments currently have little to no interoperability and must be manually operated. Existing lab equipment has its own complex software language, which siloes the data and limits automation. A few companies tried to solve this problem by adding custom integrated devices that are optimized for specific workflows, while others have built and offer cloud-based labs as a service. Given the complexity of biology and variation in experiments, we believe that R&amp;D teams will increasingly need digital tools that promote decentralized interoperability, automation, and ease of use.</p><p>We invested in Antha, developed by Synthace, which solves this problem by providing a high-level programming language and directly integrating with equipment manufacturers. While there are some pieces of automation technology in the market, Synthace is the first and only one to truly connect experiments and data. Not only are we excited about the future of true lab automation, where researchers can design their workflow and run experiments remotely via Antha-powered devices, we are also excited about using experimental data as a closed feedback loop to optimize parameters and efficiency.</p><p>The advancement of synthetic biology tools enables next generation genetic circuit and organism design, fueling applications across industrial, agbio, and medicine. Our portfolio company Ginkgo Bioworks, through its automated foundry and expertise in high-throughput organism screening, formed partnerships with Bayer to develop nitrogen fixation microbes and with Synlogic to engineer probiotics for metabolic conversion to treat disease. Arzeda uses computational protein design to create novel enzymes for products. We have seen companies such as Asimov commercializing circuit design software and Senti Bio designing next generation cell therapy via genetic circuits to sense and respond to cancer.</p><p><strong>Consumerization of Diagnostics</strong></p><p>In 2017 we also invested in Totemic Labs. Those of us who have cared for an elderly or frail loved one, know that falls are one of the biggest risk factors for increased mortality, especially if they live alone. We began looking at such technology in 2016, eventually meeting Kiran Joshi at the ideation stage. Since then, the company has made great progress and demo’ed at YC. Totemic Labs makes a device that looks like an Amazon Echo, but monitors the health and safety of senior citizens in a completely passive way. Without the use of a wearable device, Totemic Labs monitors the most salient pieces of information in a senior’s day to day life: serious health events like falls and behavioral red flags such as increased/decreased urination frequency, skipping meals, or being bedridden that can correlate with health decline. We can now give more insights into the day-to-day health and wellness of people’s elderly relatives and allow them to better manage their caregiving processes. We can’t wait for such device to transform senior care in 2018!</p><p><strong>Neurotech</strong></p><p>This year, we also spent much time exploring the neurotech space. After the genomics revolution, we were intrigued by the human brain. Ultimately, it’s what provided us with civilization development and dominance over other species on the planet. As technology advances, we still haven’t had the significant breakthroughs as we did on the genomics and cancer front in understanding the underlying biology and therapies for diseases. Broadly, we see technologies falling into one of the three sectors: measure, modulate, and emulate the brain. We predominantly explored measuring technologies below, felt that advanced modulation first needs precise measurement, and will discuss emulating technologies another day.</p><p>Overall, there has been a wealth of advancements in the space. Current electrophysiological methods for functional brain imaging such as EEG and MEG can provide high temporal resolution, but they are limited in spatial resolution and brain coverage. In contrast, functional MRI (fMRI) offers broad coverage, but it has low temporal resolution and is an indirect and incomplete measure of neural activity. Recently, we’ve seen research tools that get to higher spatial and temporal resolution with techniques such as two-photon fluorescence microscopy, fiber optics imaging, and optogenetics. Although these techniques are hard to transfer to human studies, they lay the groundwork for combining spatial and temporal understanding of mammalian brains.</p><p>To put it in context on the human side, DARPA is funding technology and research that can record 1M neurons simultaneously compared to ~100B neurons in the human brain. One problem with large-scale recordings is that the spatial and temporal resolution typically decreases as the volume of the brain to be scanned increases. This provides opportunities for devices that can measure high sensitivity at single-neuron level and high volume of neurons at longitudinal and spatial scale. In addition, because it is unclear whether measuring that many neurons is enough to decode a thought, we need tools that can help interpret cellular information and how that correlates to our physical and mental activities.</p><p>There are two applications for measuring brain activities we are excited<strong> </strong>about. Measuring brain activity can help detect health issues, make prognoses, and monitor various neurological diseases. Gathering and interpreting neural signals can also help with augmentation of the physical self in brain-machine interfaces (BCI), which include neural prosthetics. For examples, a few companies are interpreting electrode signals from the brain to predict onset of epilepsy seizures, amongst various other conditions, to help early triage and better resource allocation at hospitals. Companies such as BrainSpec and Darmiyan are building analytics on top of the MRS and MRI images, respectively, to help diagnose diseases such as cancer and Alzheimer’s. Researchers have applied machine learning to fMRI to predict and prioritize the most effective therapy for patients with depression. Neurable is applying machine learning to predict directional intentions from certain neural signals for gaming. On the augmentation through hardware side, Ipsihand is a brain-controlled glove that uses EEG and amplifier to help reroute hand control to an undamaged part of the brain. CBAS is looking to collect peripheral neural signals from amputees to establish standardized connections between signals and movements. Companies such as Paradromics and Ni2O solve the problem of connecting of thousands of probes to the processing chip. We are excited by novel technologies that can capture high spatial and temporal resolution of brain signals non-invasively and by software that can understand the meaning of underlying neural signal and memory.</p><p><strong>Computational Therapeutics</strong></p><p>Last but not least, there was a high level of innovation in computational drug discovery in 2017. From tensor networks to generative adversarial networks, we continue to seek multidisciplinary approaches of computer science, biology, chemistry, and physics can address the toughest challenges in healthcare and life sciences.</p><p>Yizhen</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e668c82e37d5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Artificial Intelligence is Transforming Drug Discovery & Development]]></title>
            <link>https://medium.com/@112capital/how-machine-learning-is-transforming-drug-discovery-51817e82c36d?source=rss-d78fc58d1c2b------2</link>
            <guid isPermaLink="false">https://medium.com/p/51817e82c36d</guid>
            <category><![CDATA[machine-learning]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[11.2 Capital]]></dc:creator>
            <pubDate>Wed, 18 Oct 2017 17:37:06 GMT</pubDate>
            <atom:updated>2019-08-09T23:46:59.924Z</atom:updated>
            <content:encoded><![CDATA[<p>According to the 2015 Tufts Center for the Study of Drug Development, it now costs $2.6B to get a new drug to market. This figure represents the average cost of total research and development dollars spent divided by the total number of drugs approved. Overtime there has been a gradual decrease in drug development efficiency, as it requires increasingly more capital to successfully bring a drug to market.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/850/1*6NMNRY7NkRPRjq5KjSDUsA.png" /><figcaption>Nature Reviews Drug Discovery 11, 191–200 (March 2012)</figcaption></figure><p>There are four primary drivers of this increase in cost and decrease in efficiency and output of the drug development process.</p><p>1. Increases in generics raise the bar for new medicine, as companies are prioritizing tougher medical challenges with lower probability of success.</p><p>2. The public and regulatory body are concerned by the safety of new technologies such as CAR-T and CRISPR, which could require additional evidence from larger studies.</p><p>3. We are trying to take advantage of the newly discovered science to make novel drugs, while still lacking the understanding of its complex biology.</p><p>4. Industry consolidation limits creative diversity.</p><p>Breaking down the $2.6B cost, about 42% is spent on preclinical discovery and animal studies while the remaining 57% is spent on human trials. There are various ways machine learning is helping to reduce those costs in both pre-clinical and clinical settings.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*zjKUeS2NxDO95HcP1KMoqQ.jpeg" /></figure><p>For example, in pre-clinical, discovery settings, pharmaceutical companies screen millions of small molecule compounds against targets, looking for some physical interaction. For example, startups such as <a href="http://www.atomwise.com/">Atomwise </a>are applying machine learning to model and predict molecular docking. The company has trained a convolutional neural network using molecule structures and binding information to predict whether existing drugs will bind to a new target. <a href="http://insilicomedicine.com/">Insilico Medicine</a> uses adversarial autoencoder to generate novel structures that will inhibit cancer cell growth. <a href="http://www.recursionpharma.com/">Recursion Pharmaceuticals</a> images tens of thousands of cells to extract structural features. Using these cellular “fingerprints” of healthy and disease cells, the company can ask whether any drug rescues diseased cells back to health. In oligonucleotide-based therapy discovery, our portfolio company <a href="https://www.deepgenomics.com/">Deep Genomics</a> uses deep learning to more accurately predict which antisense oligonucleotides (ASO) are going to work on which target. <a href="http://www.auransa.com/">Auransa</a>’s predictive engine uses human molecular data for patient subtyping and identifying responder populations. Auransa has a robust pipeline of drugs discovered via its predictive engine and anticipates filing its first IND in Q1 2020.</p><p>Similarly, when screening compounds for toxicity in pre-animal testing, current pharmaceutical process standards would physically screen the drug molecule against &lt;100 proteins/compounds that are known to cause side effects. Machine learning startups such as <a href="https://cyclicarx.com/">Cyclica</a> and <a href="http://benevolent.ai/">BenevolentAI </a>are disrupting this field. Cyclica has created a database of proteins to predict toxicity through docking and surface matching.<a href="http://benevolent.ai/"> </a>BenevolentAI employs PrOCTOR, which uses random forest and a set of molecular properties, target-based properties, and drug-likeness rule features to predict toxicity.</p><p>Importantly, the growing numbers of industry partnerships validate such applications of machine learning approaches to drug discovery and bioscience research. AstraZeneca has partnered with <a href="https://berghealth.com/company/">Berg Health</a>, which uses deep learning on clinical data and molecular data generated through mass spec of diseased vs. healthy tissues. It then ranks the genes, proteins or metabolites it finds according to their relevance to a particular disease, and determines when specific genes or proteins are associated with certain patient outcomes. Such screening is “at least 50% cheaper” than traditional methods, says CEO Dr. Niven Narain. Sanofi and GSK have partnered with UK-based <a href="https://www.exscientia.co.uk/">Exscientia</a>, which has developed a platform to design and evaluate novel compounds for predicted criteria, including potency, selectivity, and ADME, against specific targets. In addition, BenevolentAI<a href="http://benevolent.ai/"> </a>has partnered with LifeArc, and Atomwise struck a partnership with Merck.</p><p>In clinical, human-trial settings, the NIH reported that greater than 80% of clinical studies fail to meet their enrollment goals in the stated timeframes, contributing to rising drug costs. We are seeing a slew of machine learning startups looking to better match patients to clinical trials. <a href="https://deep6.ai/">Deep6 Analytics</a> applies deep learning to clinical data in the electronic health records to find patients that match trial protocol. <a href="http://mendel.ai/">Mendel.ai</a> uses NLP to comb through <a href="http://clinicaltrials.gov/">ClinicalTrials.gov</a> to provide a list of personalized trial matches to a particular patient. <a href="http://trials.ai/">Trials.ai </a>uses deep learning to help biotech/pharma companies optimize trial design.</p><p>As an early stage venture capital investor in the intersection of computer science and bioscience, We are excited about the breakthrough innovations in this space. We are seeing more and more companies — startups and established players alike — incorporating machine learning into their R&amp;D process in order to capitalize on the increasing availability of molecular and clinical data as well as advancements in computational techniques to reduce the costs and cycle times associated with drug development. Particularly, machine learning innovation has decreased drug discovery costs and increased efficiency through computational prediction of efficacy and safety. Nevertheless, in order for this interdisciplinary field to succeed, we will need access to larger amounts of data and better understanding of our biology.</p><p>Yizhen</p><p>11.2 Capital</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=51817e82c36d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Innovative Healthcare Companies Use AI to Put Patients First]]></title>
            <link>https://medium.com/@112capital/how-innovative-healthcare-companies-use-ai-to-put-patients-first-d2456295b0ed?source=rss-d78fc58d1c2b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d2456295b0ed</guid>
            <category><![CDATA[artificial-intelligence]]></category>
            <dc:creator><![CDATA[11.2 Capital]]></dc:creator>
            <pubDate>Mon, 29 May 2017 20:58:52 GMT</pubDate>
            <atom:updated>2017-05-29T20:58:52.525Z</atom:updated>
            <content:encoded><![CDATA[<p>Interview of our Founding and Managing Partner Shelley Zhuang</p><p>“If there’s any industry ripe for disruption by AI and ML applications, it’s healthcare. This week, we speak with <a href="http://www.eleventwocap.com/"><strong>ElevenTwo Capital</strong></a>’s Founder and Managing Partner Shelley Zhuang, whose investment focus (among other spaces) is on innovative healthcare services. In addition to discussion how AI is helping propel genomics, diagnostics, therapeutic treatment, and other innovations, she touches on what the healthcare space might look like in the next 10 years. For healthcare startups looking to break into the healthcare market, Zhuang doesn’t pretend to have simple answers; however, she identifies commonalities among companies that have been successful in smart preparation for meeting regulatory and other industry considerations. This interview was recorded live in San Francisco at Re-Work’s Machine Intelligence in Autonomous Vehicles Summit in March 2017.”</p><p>Check it out: <a href="https://player.fm/series/artificial-intelligence-in-industry-with-dan-faggella/how-innovative-healthcare-companies-use-ai-to-put-patients-first">https://player.fm/series/artificial-intelligence-in-industry-with-dan-faggella/how-innovative-healthcare-companies-use-ai-to-put-patients-first</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d2456295b0ed" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Data-Driven Health]]></title>
            <link>https://medium.com/@112capital/data-driven-health-843615559096?source=rss-d78fc58d1c2b------2</link>
            <guid isPermaLink="false">https://medium.com/p/843615559096</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[data-driven-health]]></category>
            <category><![CDATA[healthcare-startups]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[11.2 Capital]]></dc:creator>
            <pubDate>Mon, 06 Feb 2017 16:36:00 GMT</pubDate>
            <atom:updated>2019-07-21T17:11:52.477Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/720/1*j3biGK1l4jHFMG4qFb9ZBQ.jpeg" /><figcaption>Full resolution of the landscape can be found <a href="https://drive.google.com/file/d/0B-TSLCWdGOqNSHV4ZU9zZ3BkbTA/view?usp=sharing">here</a></figcaption></figure><p><strong>Motivation</strong></p><p>We have seen a revolution in the healthcare industry in recent years — ehealth to mhealth, influx of genomic data, and the Affordable Care Act just to name a few. Our fund, 11.2 Capital, has invested in a number of breakthrough technology companies in this revolution. We wanted to organize thoughts in the following investment areas, reflect on how we see them unfold, and understand the opportunities for innovation that will drive the future of healthcare.</p><p>As a non-traditional healthcare investor, we look for companies capitalizing on the confluence of trends transforming the healthcare industry and solving meaningful problems with core technologies. For now, we are broadly calling this space “Data-Driven Health,” but our interest and investment encompass innovations that lie beyond the title.</p><p><strong>Investment areas and companies in the landscape</strong></p><p><strong>1.</strong> <strong>Computational Health</strong></p><p>Computational health combines availability of more data and advances in software/hardware technologies to solve problems in healthcare with computation-based approaches. The explosion in volume of various kinds of data — genomic, transcriptomic, proteomic, epigenetic, metabolomic, microbiome, clinical, and behavioral — is driven by the lowering cost of data acquisition and storage. For example, sequencing a human genome used to cost around $3 billion in the 90’s. Today it only costs a few thousand dollars — a faster decline than what we observed in computing cost depicted by Moore’s Law. In addition, advances in software and hardware technologies are rapidly accelerating, particularly around artificial intelligence.</p><p>The confluence of these trends is transforming healthcare, and companies are harnessing data and applying AI to solve meaningful problems in diagnostics, therapeutics, treatment &amp; care, and clinical &amp; administrative workflows. In diagnostics, Bay Labs is applying deep learning to ultrasound imaging, to help with both acquisition and interpretation of echocardiograms. Grail and Freenome are developing blood screening tests and novel computation methods to detect cancer early. In therapeutics, Auransa has developed a computational platform that characterizes disease heterogeneity and identifies compounds that will be effective for specific patient sub-populations. Deep Genomics is building a number of machine learning modules to interpret genetic variations and how they impact various biological processes, such as splicing, in the body, discovering new drug targets for nucleic acid therapeutics. In treatment &amp; care, companies like Flatiron Health and Oncora Medical are helping physicians use historical clinical data to make better treatment decisions for patients today.</p><p>As multi-morbid patients continue to grow in volume and make up ever more of the cost of care provided, hospitals are increasingly forced to seek cost-effective, proactive, multi-touch methods to manage these patients. Companies such as Apixio enables Medicare Advantage plans to more accurately adjust risk based on patient records, and Hindsait enables payors to speed up important decisions such as prior authorizations to reduce unnecessary services. Ark One and Biome Analytics fuse multiple data sources to reveal drivers of cost and quality so that clinical teams can deliver the best possible care at the lowest cost. Outside the hospital, we see smart care coordination platforms prevent costly acute care readmissions which account for the bulk of healthcare cost. Ellipsis Health is helping care coordinators detect signs of mental disorders such as depression through automated patient voice analysis, enabling the clinician to kick-off depression protocols potentially even before patients themselves are aware of their depression. Jiseki Health is transforming care coordination by taking on risks themselves to provide social services (for example, food, transportation) to Medicare and Medicaid patients in a patient’s community.</p><p>We believe that the influx of data from the molecular to behavioral level will provide unprecedented insight into diagnosis and treatment of diseases. The interdisciplinary nature of computational health presents innovation and partnership opportunities for nimble startups. We are now at the early stage of data collection and discovery: We are still discovering new insights about our genome every day and we still know very little about our epigenome and proteome. We are excited to be in the middle of this discovery and are hopeful that this understanding will one day enable us to create a detailed molecular atlas of our body that simulates changes based on various diseases and changes in the environment. In addition, we see opportunities in technologies that help hospitals effectively deploy increasingly costly labor resources and meaningfully reduce supply cost, predict acute events, ensure delivery of care in the most appropriate setting, and enhance patient experience and health outcomes for an ever older, sicker, and more complex population. The challenges facing healthcare providers and payers are significant and so are the opportunities for innovative companies with effective solutions. By computing health, we can design treatments that are targeted, precise, and uniquely suited for individuals.</p><p><strong>2.</strong> <strong>Enabling Tools</strong></p><p>We are continuing to see innovations in the tools space that will enable cheaper and faster access to data across the genome, epigenome, transcriptome, proteome, epigenome, metabolome, microbiome, etc. For example, Loop Genomics is developing a sample preparation technology that will enable long read sequencing with existing Illumina instruments. Genturi is developing a nanofluidic device that will enable cheaper and faster access to structural variants up to chromosome-length in a genome. In epigenetics, companies such as Epinomics and Genome Profiling are developing genome-wide methylation and histone-modification profiling platforms.</p><p>We are also seeing companies adding dimensions and contexts to the omics data. For example, Readcoor is commercializing a spatial gene sequencing technology that simultaneously reads RNA sequences and visualizes their 3D coordinates within whole cells and tissues. Single-cell analysis is particularly important in cancer where bulk analyses miss rare cells and cell heterogeneity. For such analysis, Cellular Research is working on gene expression, and Zephyrus is working with proteomic data.</p><p>Besides reading DNA, writing (DNA synthesis) and editing are equally important in basic biological research, biofuels, agriculture, drug discovery, and gene therapy. Molecular Assemblies is developing an enzymatic method to write long, high-fidelity, and cost-effective DNA to accelerate the emerging precision medicine and synthetic biology fields. In genome editing, CRISPR has revolutionized the space by providing a cost-effective, multiplex molecular tool to edit almost any genome of choice. Due to its high precision and accessibility, researchers are expanding its use to gene silencing and activation.</p><p>In addition to innovations in the reading and writing of omics data, life sciences experiments are moving toward the cloud and automation to increase efficiency. As an active tech investor in robotics (Cruise Automation, Savioke, Kindred), we are excited by companies bringing robotics and automation to research tools. For example, companies such as Emerald Cloud Labs and Transcriptic are both providing robotic cloud labs, so any researcher can run experiments remotely. Similarly, Vium is providing rodent cages equipped with sensors and high-definition cameras, among other technology, so researchers can run animal experiments remotely. Companies such as Twist, Gen9, and Synthego are applying large-scale automation to make DNA and RNA synthesis cheaper and higher quality. Notable Labs is offering a high-throughput robotics platform to screen drug combinations that will work best on individual cancer patients. Thrive Bioscience is developing a counter-top instrument to fully automate cell culturing. All these companies provide tools and services to make life sciences R&amp;D more efficient by automating certain processes that are currently manual and error prone.</p><p>As we continue to see development of tools to access and analyze multi-omics data in a high-throughput and cost-effective way, we are optimistic that these innovations will be incorporated into clinical care, improving how omics data is currently enabling precision medicine. With robotics and automation, experiments will be conducted in a cheaper, faster, and more reproducible manner, fueling scientific discovery and clinical translation.</p><p><strong>3.</strong> <strong>Consumerization</strong></p><p>With health information and education ever more accessible, patients are increasingly taking an active role in their care experience, creating “consumerization” of healthcare, manifested across diagnostics, care delivery, and insurance. In diagnostics, Diassess is developing a portable, disposable device for pathogen detection. The idea is to market this first in point-of-care settings and eventually over the counter, allowing consumers to test for infectious diseases at home. There are many other examples of consumerization of diagnostics, including Scanadu, Cor, and Cue, which are bringing vital sign monitoring, urine analysis, blood chemistry, and other diagnostics directly into the home. In care delivery, One Medical has built a consumer-friendly primary care network, Pager allows consumers can summon doctors on demand, and Forward uses new technology to create a baseline of personal health data, with AI-assisted follow-ups. Even in the insurance industry, companies such as Clover Health and Oscar Health are both providing more consumer-friendly health insurance plans that better serve the needs of different patient populations.</p><p>Point of care and home-based diagnostics will increasingly enable consumers to find out about their conditions in a setting of their choice, rather than waiting days for results, while decreasing unnecessary emergency department admissions and even visits to general practitioners. A recent <a href="https://www.svb.com/News/Company-News/Big-Data-and-Artificial-Intelligence-Hold-Greatest-Promise-for-Healthcare-Technologies/">survey</a> conducted by Silicon Valley Bank found that patient and clinical adoption remain the biggest industry challenge. We are excited about diagnostics moving toward being less invasive and more accessible, combining analytics and what’s measurable to accurately infer health vitals.</p><p><strong>4.</strong> <strong>Digital Therapeutics</strong></p><p>From small-molecules to biologics to immunotherapy in therapeutic innovation, we believe that digital therapeutics is one of the treatment paradigms, especially in the field of behavior-mediated conditions. Companies are digitalizing care in pre-diabetes, diabetes, heart disease, kidney disorders, sleep, and various types of psychological disorders, with the shared goal of cost-effective disease management and treatment. Hinge Health is digitizing the delivery of best practice care of musculoskeletal disorders, one of the top three cost drivers for self-insured employers. Results from early pilots show that participants see a reduction in pain and desire for surgery, helping employers save costs. Pharmaceutical companies are taking notice in digital therapeutics and working more closely with startups to develop “beyond the pill” approach to patient health. Akili Interactive has partnered with Pfizer to measure the effectiveness of their digital game to slow down the progression of Alzheimer’s. Amgen has a digital health focus that aims to increase drug adherence. We see these non-traditional partnerships will continue to grow.</p><p>Our country is the most-drugged country in the world, increasing cost of care as well as experienced side effects and toxicities from pharmaceutical drugs. Digital therapeutics serves as an effective and safe alternative to this epidemic. We’ve seen successful companies focus on strong marketing, seamless integration into the patient-provider workflow, and deep understanding of various types of markets in care provisioning. As core technology investors, we believe that digital therapeutic companies with a defensible and effective approach will create long lasting impact on patient health.</p><p><strong>5.</strong> <strong>Synthetic biology</strong></p><p>Engineering biological systems is not a new field, but our increasing understanding of biology at the cellular level has enabled us to more effectively manipulate organisms to perform certain functions and create valuable products. We saw a wave of biofuel companies come and go, but newer entrants are seeing market demand from high-value products. For example, Ginkgo Bioworks is on the forefront of engineering microbes to produce flavors and fragrances at a cheaper cost than traditional methods. Antheia is engineering yeast to make opioids, and Geltor has created a microbe that cost effectively manufactures collagen.</p><p>As we collect an increasing amount of molecular data, we continue to look for ways to gain new insights into the functions by leveraging bioinformatics and machine learning. We can then extract and apply useful gene functions to various industries.</p><p>Precision medicine is here to stay and it requires companies to have the biology, engineering, data science, and clinical talent to solve meaningful problems. We’d love to talk to anyone using an interdisciplinary approach to better our health. We hope to continue this conversation and welcome feedback if there are categories or companies missing. Drop us a note at yizhen[at]112capital.com or shelley[at]112capital.com. Thank you to Chris Armstrong, Zavain Dar, Scott Barclay and many others for sharing your perspectives.</p><p><strong>About 11.2 Capital</strong></p><p>11.2 Capital is an early stage venture capital fund based in San Francisco, investing in breakthrough technology in artificial intelligence, AR/VR, robotics, space, and data-driven health. 11.2 Capital is an investor in Bay Labs, Auransa, Deep Genomics, Loop Genomics, Genturi, Molecular Assemblies, Notable Labs, Diassess, Hinge Health, and Ginkgo Bioworks.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=843615559096" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>